332 related articles for article (PubMed ID: 30796524)
1. Osteoporosis therapy in patients with inflammatory rheumatic diseases and osteonecrosis of the jaw.
Schwaneck EC; Streit A; Krone M; Hartmann S; Müller-Richter U; Kübler AC; Gadeholt O; Schmalzing M; Tony HP; Brands RC
Z Rheumatol; 2020 Mar; 79(2):203-209. PubMed ID: 30796524
[TBL] [Abstract][Full Text] [Related]
2. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
[TBL] [Abstract][Full Text] [Related]
3. Medication-related osteonecrosis of the jaw in osteoporotic patients: prevention and management.
Chan BH; Yee R; Puvanendran R; Ang SB
Singapore Med J; 2018 Feb; 59(2):70-75. PubMed ID: 29568850
[TBL] [Abstract][Full Text] [Related]
4. Medication-Related Osteonecrosis of the Jaw Around Dental Implants: Implant Surgery-Triggered or Implant Presence-Triggered Osteonecrosis?
Giovannacci I; Meleti M; Manfredi M; Mortellaro C; Greco Lucchina A; Bonanini M; Vescovi P
J Craniofac Surg; 2016 May; 27(3):697-701. PubMed ID: 27092912
[TBL] [Abstract][Full Text] [Related]
5. Emerging antiresorptive medications and their potential implications for dental surgeries.
Aminoshariae A; Donaldson M; Horan M; Mackey SA; Kulild JC; Baur D
J Am Dent Assoc; 2022 Jul; 153(7):649-658. PubMed ID: 35277242
[TBL] [Abstract][Full Text] [Related]
6. Osteonecrosis of the jaws in patients under osteoporosis treatment: a nine-year experience report.
Penoni DC; Canellas JVS; Silami MANC; Sader F; Pimentel GS; Leão ATT
Arch Endocrinol Metab; 2023 May; 67(4):e000612. PubMed ID: 37252700
[TBL] [Abstract][Full Text] [Related]
7. Surgical therapy for medication-related osteonecrosis of the jaw in osteoporotic patients treated with antiresorptive agents.
Hauer L; Jambura J; Hrusak D; Chalupova M; Posta P; Rusnak S; Vyskocil V
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Mar; 164(1):100-107. PubMed ID: 30647474
[TBL] [Abstract][Full Text] [Related]
8. Medication-related osteonecrosis of the jaw after once-a-year intravenous zoledronic acid infusion for osteoporosis: Report of eight cases.
Favia G; Tempesta A; Limongelli L; Crincoli V; Maiorano E
Quintessence Int; 2016; 47(5):433-40. PubMed ID: 26665262
[TBL] [Abstract][Full Text] [Related]
9. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
Dodson TB
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
[TBL] [Abstract][Full Text] [Related]
10. Medication-related osteonecrosis of the jaw: knowledge and perceptions of medical professionals on the usage of bone modifying agents and dental referrals.
Acharya S; Patil V; Ravindranath V; Kudva A; Nikhil K
J Med Life; 2022 Mar; 15(3):368-373. PubMed ID: 35449990
[TBL] [Abstract][Full Text] [Related]
11. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
[TBL] [Abstract][Full Text] [Related]
12. A Study of Oral Health Parameters and the Properties and Composition of Saliva in Oncological Patients with and without Medication-Related Osteonecrosis of the Jaw Who Take Bisphosphonates.
Sobczak-Jaskow H; Kochańska B; Drogoszewska B
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374277
[No Abstract] [Full Text] [Related]
13. Prevalence and risk factors of medication-related osteonecrosis of the jaw in osteoporotic and breast cancer patients: a cross-sectional study.
Soares AL; Simon S; Gebrim LH; Nazário ACP; Lazaretti-Castro M
Support Care Cancer; 2020 May; 28(5):2265-2271. PubMed ID: 31468192
[TBL] [Abstract][Full Text] [Related]
14. Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis.
Bagan J; Peydró A; Calvo J; Leopoldo M; Jiménez Y; Bagan L
Oral Dis; 2016 May; 22(4):324-9. PubMed ID: 26818808
[TBL] [Abstract][Full Text] [Related]
15. Incidence and trend of antiresorptive agent-related osteonecrosis of the jaw from 2016 to 2020 in Kure, Japan.
Kunihara T; Tohmori H; Tsukamoto M; Kobayashi M; Okumura T; Teramoto H; Hamasaki T; Yamasaki T; Nakagawa T; Okimoto N; Fujiwara S
Osteoporos Int; 2023 Jun; 34(6):1101-1109. PubMed ID: 37002373
[TBL] [Abstract][Full Text] [Related]
16. What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review.
Aljohani S; Fliefel R; Ihbe J; Kühnisch J; Ehrenfeld M; Otto S
J Craniomaxillofac Surg; 2017 Sep; 45(9):1493-1502. PubMed ID: 28687467
[TBL] [Abstract][Full Text] [Related]
17. [Bisphosphonate-related osteonecrosis of the jaws].
Sogacheva VV; Syomkin VA
Stomatologiia (Mosk); 2022; 101(6):85-90. PubMed ID: 36562373
[TBL] [Abstract][Full Text] [Related]
18. Impacts of bisphosphonates on the bone and its surrounding tissues: mechanistic insights into medication-related osteonecrosis of the jaw.
Srivichit B; Thonusin C; Chattipakorn N; Chattipakorn SC
Arch Toxicol; 2022 May; 96(5):1227-1255. PubMed ID: 35199244
[TBL] [Abstract][Full Text] [Related]
19. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
20. A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients.
Jung S; Kim J; Park JH; Kim KY; Kim HJ; Park W
Sci Rep; 2022 May; 12(1):8641. PubMed ID: 35606457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
